Fig. 6From: Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVRThe anti-tumor effects of liothyronine on MC38 tumor model. a Tumor growth curve of MC38 tumor-bearing mice treated with normal saline, low dose (1.5 mg/kg) and high dose (5 mg/kg) of liothyronine by intraperitoneal injection every other day. (n = 7, *P < 0.05, **P < 0.01). b Flow cytometry analysis of the proportion of CD8+ T cells infiltration at the tumor site of tumor-bearing mice. Intracellular IFN-γ staining assay of tumor infiltrating lymphocytes c, splenocytes d and tumor draining lymph node e. f Tumor growth curves of tumor-bearing mice injected with rat IgG, CD4 or CD8 depletion antibodies treated by control or liothyronine (5 mg/kg). (n = 4, *P < 0.05). g Tumor growth curves of tumor-bearing mice injected with mouse IgG or NK1.1 depletion antibody treated by control or liothyronine (5 mg/kg). (n = 4, *P < 0.05)Back to article page